News Updates |
 |
Interest Grows in Long-Acting Injectables for HIV Treatment
Pharmacy Times | March 17, 2023
|
 |
Implementing Long-acting Injectable PrEP with an Eye Toward Equity: Yale's Dr. LaRon ...
HIV.gov | March 2, 2023
|
 |
New HIV Treatment and PrEP Guidelines
POZ Magazine | February 13, 2023
|
 |
Sunlenca Looks Great for Highly Drug-Resistant HIV. Will It Serve a Broader Purpose?
TheBody | January 31, 2023
|
 |
Baseline Resistance to Second-Generation INSTIs, First-Line NRTIs Unlikely in HIV
Infectious Disease Advisor | January 30, 2023
|
 |
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
Lancet HIV. 2023 Jan;10(1):e15-e23. doi: 10.1016/S2352-3018(22)00291-0.
|
 |
FDA approves Sunlenca for treatment-resistant HIV
Medical Xpress | December 29, 2022
|
 |
Treatment of ocular-involving monkeypox virus with topical trifluridine and oral tecovirimat in the 2022 monkeypox virus outbreak
Am J Ophthalmol Case Rep. 2022 Dec 13;101779. doi: 10.1016/j.ajoc.2022.101779.
|
 |
ContagionLive | December 9, 2022 |
 |
Antiretroviral Drugs for HIV Clinical Practice Guidelines (IAS,2022)
Medscape | December 9, 2022 |
 |
Do Antidepressants Make HIV Meds Less Effective?
Plus Magazine | December 9, 2022 |
 |
kpbs.org | December 8, 2022 |
 |
Toolkit: Long-Acting Injectables in HIV Treatment
TargetHIV | November 15, 2022
|
 |
Fostemsavir Plus Optimized Background Therapy May Be Viable for MDR HIV |
 |
Dolutegravir Effectively Suppresses HIV in Pregnant Women
Contagion Live | November 2, 2022 |
 |
FDA reports shortages of amoxicillin (November 1, 2022)
The Hill | November 1, 2022 |
 |
HepB-CpG Vaccination Achieves Maximum Seroprotection in Patients With HIV
Infectious Disease Advisor | October 28, 2022 |
 |
Tybost (Cobicistat) - Oral: Uses, Side Effects, Dosages, Interactions
Verywell Health | October 28, 2022 |
 |
European Medicines Agency Validates Viiv Healthcare's Marketing Authorisation Application For Cabotegravir Long-Acting Injectable For HIV Prevention
ViiV Healthcare | October 28, 2022 |
 |
Gilead's latest Biktarvy data offers hope to HIV patients
PMLiVE | October 25, 2022 |
 |
A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
Retrovirology. 2022 Oct 22;19(1):22. doi: 10.1186/s12977-022-00608-1. |
 |
Tolerability Drives Most ART Switch Decisions in Patients Living With HIV/AIDS
Contagion Live | October 21, 2022 |
 |
Long-Term Biktarvy Resulted in High Rates of Viral Suppression
Infectious Disease Special Edition | October 20, 2022 |
|
|